Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Formyl Peptide Receptors
More Information »The formyl peptide receptor family, FPR1, FPR2 and FPR3 (formerly FPR, FPRL1 and FPRL2 respectively) are Gi-protein-coupled receptors that are expressed mainly by mammalian phagocytic leukocytes. FPRs are involved in antibacterial host defence and inflammation.
Formyl Peptide Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 1921 | N-Formyl-Met-Leu-Phe |
| Endogenous FPR1 agonist | |
| 2826 | FPR A14 |
| FPR agonist | |
| 3537 | MMK 1 |
| Potent and selective FPR2 agonist | |
| 1799 | WKYMVM |
| Selective FPR2 and FPR3 receptor agonist | |
| 1800 | WKYMVm |
| FPR1, FPR2 and FPR3 receptor agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 3730 | Boc-MLF |
| FPR1 antagonist | |
| 4611 | PBP 10 |
| Selective FPR2 antagonist; cell permeable | |
| 2262 | WRW4 |
| Selective FPR2 antagonist | |
Ligands |
|
Cat.No. |
Product Name / Activity |
| 3231 | Ac9-25 |
| Annexin I N-terminal peptide. Acts as a FPR1 ligand | |
Related Categories
Quick Order
Find multiple products by catalog number
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.